Thermo Fisher Scientific Inc. (TMO) Stock Price & Analysis
Thermo Fisher Scientific Inc. (TMO) fell 0.71% to USD 568.26 as of July 25, 2026 at 01:12 UTC, according to Nexqual real-time market data.
TMO last closed at USD 572.32; the session ranged USD 555.98–573.64 on volume of 2,443,217 shares. Market capitalization is —, with a 52-week range of USD 435.27–643.99 (NYQ). Source: Nexqual, July 25, 2026 at 01:12 UTC.
Key Statistics (as of July 25, 2026 at 01:12 UTC)
| Price | USD 568.26 |
|---|---|
| Change | ▼ 0.71% (down) |
| Previous Close | USD 572.32 |
| Open | USD 570 |
| Day Range | USD 555.98 – 573.64 |
| 52-Week Range | USD 435.27 – 643.99 |
| Volume | 2,443,217 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (TMO)
Nexqual's technical model rates TMO "BUY" based on 5 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 01:12 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 70.93 (overbought) |
| vs SMA50 | Above (USD 491.99) |
| MACD | 16.81 (positive) |
Analyst Ratings (TMO)
Wall Street analysts rate TMO "Buy" based on 26 analysts, with a mean price target of USD 615.12 (range USD 510–750), per Nexqual as of July 25, 2026 at 01:12 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 26 |
| Mean Target | USD 615.12 |
| High Target | USD 750 |
| Low Target | USD 510 |
| Buy / Hold / Sell | 21 / 7 / 0 |
Earnings (TMO)
| Next Earnings Date | 2026-10-21 |
|---|---|
| EPS Estimate | USD 6.39 |
| Revenue Estimate | $11.94B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 6.03 vs est 5.71 ▲ beat |
| 2026-03-31 | USD 5.44 vs est 5.24 ▲ beat |
| 2025-12-31 | USD 6.57 vs est 6.45 ▲ beat |
| 2025-09-30 | USD 5.79 vs est 5.5 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Financials & Fundamentals (TMO)
| Total Revenue | $46.34B |
|---|---|
| Revenue Growth (YoY) | +10.50% |
| Gross Margin | +40.87% |
| Operating Margin | +18.22% |
| Profit Margin | +15.04% |
| ROE | +13.51% |
| Debt / Equity | 80.58 |
| Current Ratio | 1.55 |
| Total Cash | $4.06B |
| Total Debt | $42.55B |
| Free Cash Flow | $6.18B |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Financial Health Score (TMO)
Nexqual rates Thermo Fisher Scientific Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 01:12 UTC.
| Growth | Mixed — Revenue +3.9% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 41%, operating 18% |
| Balance Sheet | Mixed — $4.06B cash vs $42.5B debt |
| Cash Flow | Solid — FCF $6.18B, 14% margin |
| Efficiency | Mixed — ROE 14%, ROA 5.1% |
Ownership (TMO)
| Insider Ownership | +0.15% |
|---|---|
| Institutional Ownership | +93.94% |
| Float | 370.05M |
| Short % of Float | +1.44% |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Leadership (TMO)
Thermo Fisher Scientific Inc. is led by Marc N. Casper (age 57), Chairman & CEO, per Nexqual as of July 25, 2026 at 01:12 UTC.
| Chairman & CEO | Marc N. Casper (age 57) |
|---|---|
| President, COO & President of Products and Technologies | Gianluca Pettiti (age 46) |
| Senior VP & CFO | James R. Meyer (age 45) |
| Chief Scientific Officer | Karen E. Nelson |
| Vice President of Investor Relations | Rafael Tejada |
Major Backers & Investors (TMO)
Notable institutional backers of Thermo Fisher Scientific Inc. include Morgan Stanley, FMR, LLC, Fidelity, according to Nexqual as of July 25, 2026 at 01:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 2.92% |
| FMR, LLC | 2.9% |
| Fidelity | 1.97% |
| Franklin Resources, Inc. | 1.83% |
| JPMorgan | 1.83% |
| Capital Group | 1.79% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 13.76% |
| BlackRock | 9.52% |
| State Street | 5.71% |
| Geode Capital | 2.26% |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
From Thermo Fisher Scientific Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Department of Health and Human Services (the DHHS), the European Medicines Agency (the EMA), the EU member states and other comparable agencies and, in the future, any changes to such laws and regulations could adversely affect us.
- We also depend in part on our trademarks and the strength of our proprietary brands, which we consider important to our business.
- Patents may not be issued for any pending or future patent applications owned by or licensed to us, and the claims allowed under any issued patents may not be sufficiently broad to protect our technology.
- In addition, competitors may design around our technology or develop competing technologies.
Partnerships
- In addition, we have availability to borrow under a revolving credit facility that provides for up to $5.00 billion of unsecured multi-currency revolving credit (the Facility).
- On November 6, 2025, the Board of Directors authorized the repurchase of up to $5.00 billion the company's common stock.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DHR | Danaher Corporation | USD 191.5 | ▲ 6.9% |
| SYK | Stryker Corporation | USD 330.25 | ▲ 6.79% |
| ZTS | Zoetis Inc. | USD 75.35 | ▲ 1.56% |
| BDX | Becton, Dickinson and Company | USD 156.36 | ▲ 2.09% |
| ISRG | Intuitive Surgical, Inc. | USD 337.5 | ▼ 0.94% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:12 UTC. This page is informational and not investment advice.